Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bristol-myers squibb
11
×
life sciences
national blog main
11
×
national top stories
san diego blog main
san diego top stories
san francisco blog main
new york blog main
new york top stories
san francisco top stories
boston blog main
boston top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
clinical trials
pfizer
merck
nonalcoholic steatohepatitis
abbvie
biogen
cancer
celgene
medicare
nash
startups
aducanumab
What
drug
11
×
bio
roundup
nash
new
news
approved
disease
liver
medical
week
advanced
alzheimer’s
approval
biogen
biogen’s
biotech
cancer
companies
conference
data
fatty
known
prices
pricing
race
adu
aducanumab
advantages
alnylam’s
amyloid
angst
annual
arrival
assessed
athena
attention
award
away
bagged
Language
unset
Current search:
drug
×
" national blog main "
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push